INTS

Business Context and Reporting Period

Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Intensity is a late-stage clinical biotechnology company developing INT230-6, an intratumoral (IT) cancer therapy. The product combines cisplatin and vinblastine sulfate with a proprietary amphiphilic molecule (SHAO) to overcome tumor microenvironment barriers. The company has no commercial revenue and relies on equity financing.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no debt as of December 31, 2025.

Material Changes vs. Prior Period

• Reduced Burn Rate: Net loss decreased by approximately 29% ($4.7 million) compared to 2024, driven primarily by a 35% reduction in Research and Development (R&D) expenses.
• Clinical Trial Pauses: R&D expense reduction was largely due to pausing new site activations and patient enrollments in the Phase 3 INVINCIBLE-3 Study (March 2025) and the Phase 2 INVINCIBLE-4 Study (September 2025) due to funding constraints.
• Capital Raising: The company significantly increased cash reserves through multiple financing activities in 2025, including a registered direct offering ($4.0 million gross), a public offering ($2.35 million gross), and At-The-Market (ATM) offerings ($11.6 million gross), resulting in a net cash increase of $9.3 million for the year.
• Stock Split: A 1-for-25 reverse stock split was effected on February 19, 2026. All historical share and per-share data in the filing have been adjusted to reflect this split.

Guidance, Outlook, and Risks

• Going Concern Warning: The independent auditor has issued a report indicating "substantial doubt" about the company's ability to continue as a going concern due to recurring losses and negative cash flows. Management projects cash will sustain operations only into the second quarter of 2027.
• Financing Needs: The company explicitly states it will need to raise substantial additional funding to resume clinical trials and continue operations. Failure to secure capital could force delays or termination of development programs.
• Clinical Outlook:
  • INVINCIBLE-3 (Phase 3 Sarcoma): Enrollment paused in March 2025 with 21 patients enrolled. Resumption is contingent on funding.
  • INVINCIBLE-4 (Phase 2 Breast Cancer): Enrollment paused in September 2025 to revise dosing due to localized skin irritation. Approval to resume was granted in March 2026, with enrollment expected to restart in Q2 2026.
• Regulatory Status: The company has received orphan drug designation for soft tissue sarcoma and has agreed on a Chemistry, Manufacturing, and Controls (CMC) plan with the FDA for Phase 3 and product registration.
• Key Risks: Dependence on a single product candidate, inability to secure future financing, potential delisting from Nasdaq if minimum bid price requirements are not met (though compliance was regained in March 2026), and the inherent risks of clinical trial failure.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the management projection that current cash ($11.9 million) is sufficient only through Q2 2027.
• Financing Timeline: Monitor upcoming equity offerings or debt financings required to restart the paused Phase 3 and Phase 2 trials.
• Clinical Resumption: Confirm the actual restart date of patient enrollment for the INVINCIBLE-3 and INVINCIBLE-4 studies following the Q2 2026 target.
• Nasdaq Compliance: Track the stock price to ensure continued compliance with the $1.00 minimum bid price requirement, given the recent history of non-compliance notices.
• Reverse Stock Split Impact: Review the impact of the 1-for-25 reverse stock split on liquidity and market perception.